Prognostic Value of the HALP Score Compared with Other Inflammatory and Nutritional Indices in IgA Nephropathy

HALP评分与其他炎症和营养指标在IgA肾病预后价值比较

阅读:1

Abstract

PURPOSE: IgA nephropathy (IgAN) is the most common primary glomerulonephritis and is characterized by highly variable renal outcomes. Conventional prognostic factors, including proteinuria, hypertension, estimated glomerular filtration rate (eGFR), and the MEST-C classification, provide limited predictive accuracy. This study aimed to evaluate the prognostic value of inflammatory and nutritional indices, particularly the Hemoglobin-Albumin-Lymphocyte-Platelet (HALP) score, in patients with IgAN. PATIENTS AND METHODS: This retrospective cohort included 204 patients with biopsy-proven IgAN. Baseline demographic, clinical, laboratory, and histopathological data were collected. Inflammatory and nutritional indices (HALP, Systemic Immune-Inflammation Index [SII], Neutrophil-to-Lymphocyte Ratio [NLR], Platelet-to-Lymphocyte Ratio [PLR], Glasgow Prognostic Score [GPS/mGPS], and Controlling Nutritional Status [CONUT]) were calculated from routine laboratory parameters. Associations with renal outcomes, particularly progression to end-stage kidney disease (ESKD), were analyzed using Cox regression, Kaplan-Meier survival, and receiver operating characteristic (ROC) analyses. RESULTS: During a median follow-up of 39.5 months, 17.1% of patients progressed to ESKD. Higher HALP scores were significantly associated with better renal survival, whereas other indices showed no consistent prognostic value. In multivariate analysis, HALP remained an independent predictor of renal outcome (hazard ratio = 0.13; p < 0.001). ROC analysis confirmed its prognostic performance (AUC = 0.65; 95% CI: 0.56-0.74; p < 0.001) with an optimal cut-off value of 42.4 (sensitivity: 72.7%; specificity: 55.0%). CONCLUSION: The HALP score is a strong and independent prognostic biomarker in IgAN, outperforming other inflammatory and nutritional indices. Incorporating HALP into current risk-stratification models may enhance prognostic assessment and guide clinical management.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。